Problem: Lack of truly tumour-specific antigens available

Bi-Cygni®

Improves therapeutic index through targeting a unique cancer-specific cell surface antigen fingerprint, absent from healthy cells

 
 

Key Personnel

Norman Molyneux 

Chairman

Tiffany Thorn

Founder & CEO

Richard Bethell

Chief Scientific Officer

Michael Carter

Non-Executive Director

 
 
For any partnership or investment enquiries